Name: | Hideki Kambara |
Title: | Honorary Fellow of Hitachi Ltd., President of frontierbiosystems.com |
Affiliation: | Frontierbiosystems.Inc, Japan |
Email: | hi4512kam@yahoo.co.jp |
100-word biography: | He was engaged in developing new ionization technologies (LC/MS, matrix assisted SIMS, etc.) for mass spectrometry of bioorganic compounds from 1977 to 1985. He started to develop fluorescent DNA sequencers at 1982. Since then he has been engaged in developing technologies for DNA analysis. He developed capillary array DNA sequencers which were commercialized to contribute greatly to the completion of the human genome project. He started to develop technologies for single cell analysis at 2005. Now he is much interested in developing tools for site specific tissue analysis at single cell resolution. |
Title: | The development of DNA related technologies |
Abstract: | The development of DNA analysis tools can be divided into 5 stages. The 1st stage; from autoradiography to automated DNA sequencers. The 2nd stage; high throughput DNA sequencers for the Huma Genome Project. The 3rd stage; DNA analysis for medical applications. The4th stage; ensemble approach to single object approach (single-cell analysis). The 5th stage; site-specific tissue analysis. The site-specific tissue analysis is getting more and more important to understand tissue functions. We have developed a micro-biopsy system for the tissue analysis. It has a spinning narrow hollow punching needle to obtain micro-dissections having diameters of 0.05-0.2mm from any types of tissue samples. |
Other: |
Name: | Jun Yu |
Title: | Professor |
Affiliation: | University of Chinese Academy of Sciences (UCAS). |
Email: | junyu@big.ac.cn |
100-word biography: | Jun YU is an endowed professor of University of Chinese Academy of Sciences (UCAS). He obtained his BS degree from Department of Chemistry, Jilin University in 1983 and PhD degree in Biomedical Sciences from New York University School of Medicine in 1990. He joined the University of Washington Human Genome Center in 1993 after a scholarship-supported postdoctoral research as Research Assistant Professor of NYU. He established both the Human Genome Center at the Institute of Genetics in 1998 and Beijing Institute of Genomics in 2003 at CAS. After having served his directorship for the two institutions in two terms, he has focused his research interests to scientific instrumentation. He has published over 350 peer-reviewed papers and supervised over 100 graduate students. He has won numerous scientific awards, including TWAS Prize in Agricultural Sciences for 2012; Outstanding Science and Technology Achievements (2003), CAS; “Qiushi” Annual Award for Scientific Achievement (2002); Young Investigator Award for Oversea Collaboration, the Natural Science Foundation of P. R. China (1999); American Foundation for Urological Diseases Ph.D. Research Scholar (1991); China-US Biology Examination and Application (CUSBEA) Scholarship for Ph.D. Candidate (1983). |
Title: | Genomics and Human Life: Challenges from Technology and Intelligence |
Abstract: | Abstract: 20 years after 20 the first human genome was sequenced, initiatives to sequence every person’s genome have been launched in many nations, attributable largely to technology advancements in DNA sequencing and data analysis. New challenges also become obvious where directly sequencing RNA including its covalently-modified nucleotides and AI-directed structure prediction is one of them. Another key challenge involved engagement of people who are enrolled in the Digital Personal Genome for healthcare purposes and health management over life-span. Meeting these two challenges with distinct goals is what we think hard and must do in well the next decade or two. |
Name: | Ulf Landegren |
Title: | Professor |
Affiliation: | Department of Immunology, Genetics and Pathology, Uppsala University, sweden |
Email: | ulf.landegren@igp.uu.se |
100-word biography: | Ulf Landegren received his MD and PhD in Uppsala, Sweden, before spending five years at California Institute of Technology. As professor of molecular medicine in Uppsala his research focuses on developing molecular tools with a potential to meet important medical needs first focused on analyzing genetic variation with techniques such as oligonucleotide ligation assays and padlock probes. In later work his lab showed that pairs of oligonucleotide-conjugated antibodies can allow high- throughput, high-performance analysis of protein expression levels in liquid samples and for imaging their distribution in situ using a family of proximity ligation assays. Professor Landegren is a member of EMBO, the Royal Swedish Academy of Sciences, the European Academies’ Scientific Advisory Committee (EASAC), and the Royal Society of Sciences at Uppsala. He is member of several academic or industrial boards and advisory boards. He has authored 224 peer-reviewed publications, and he is inventor of 46 patents or applications. Work in his lab has so far given rise to 12 spin-out companies with a combined staff of more than 400 people, including two companies that are now publicly traded (Olink Proteomics and Q-linea). Technologies from his lab have been licensed to many leading international biotech and diagnostic companies. |
Title: | Molecular tools for biomarker analysis |
Abstract: | Efficient tools for biomarker analysis are needed to diagnose diseases and identify how best to treat these. My talk will deal with three approaches to examine different classes of biomarkers, building on common strategic molecular elements. A fundamental assumption in our work is that stringent analysis will require highly specific assay techniques, and that troubling cross reactivity can be minimized in assays that depend on multiple target recognition events. In a first segment I will describe the technology behind the multiplex proximity extension assays for protein measurements in liquid samples. I will give a few examples from our own work how the assays may be applied in an increasing range of situations. Next, I will describe the analogous need for panels of high-performance in situ assays to image proteins and their patterns of interactions and modifications that reflect activity states. I will describe work in my lab using in situ proximity ligation assays to better characterize tumor cells and tissues and their drug responses. Finally, tumor-specific mutations represent highly specific markers of those malignancies, and sufficiently specific and selective assays can assist in monitoring the progress of disease and of therapy. I will describe a novel technique – SafeLock probes - for detecting exceedingly rare point mutations from as little as one malignant cell in 100 000 nucleated blood or bone marrow cells. The assay has been adapted to conform to routine clinical workflow for therapy follow-up in acute myeloid leukemia. Disclaimer. UL is founder and shareholder of Olink, Navinci and Rarity, commercializing techniques from his laboratory. |
Other: |
|
|